Keywords: Data Acquisition, CancerIn vivo 1H/31P MRS were used to monitor the effects of Kinase Inhibitor (KI) therapy in two metabolically different human melanoma xenografts models. Our goal is to determine the metabolic changes in human melanoma xenograft models when treated with two KIs, a BRAF and a MEK inhibitor. KI combination is more effective than single-drug therapy. Differences in relative levels of metabolites and bioenergetics between two human melanoma xenografts models may produce differential therapeutic responses to BRAF and MEK inhibitors. In melanoma, metabolic changes in response to targeted kinase inhibitor therapy occur rapidly and are connected to subsequent tumor response.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords